Abbott Laboratories beat fourth-quarter 2021 profit and sales estimates, aided by robust sales of COVID-19 test kits and strong demand for the company’s diagnostics products, but forecast lower-than-expected COVID-19 testing sales in 2022 due to uncertainties around the future of the pandemic.

AstraZeneca reported Covid-19 vaccine sales of $1.05 billion for third-quarter 2021, with Vaxzevria contributing 1 percent to the company’s profit for the quarter.

AbbVie Inc. on Oct. 29 raised the company’s 2021 adjusted profit forecast for the third time this year after a stellar performance by newer medicines helped the U.S. drugmaker beat Wall Street estimates for third-quarter profit and revenue.

Bristol Myers Squibb Co. reported lower-than-expected first-quarter profit on April 29 as sales of the company’s high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.